key: cord-0817407-cltnk0rg authors: Montrone, Michele; Catino, Annamaria; Palmieri, Vincenzo Ostilio; Longo, Vito; Galetta, Domenico title: Favourable outcome of COVID-19 in an ALK-positive NSCLC patient receiving Alectinib date: 2020-08-11 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.07.030 sha: ee7e9112aee4c4c5d525c995621b84553e120957 doc_id: 817407 cord_uid: cltnk0rg nan A study published before this pandemic showed higher mortality from viral pneumonia in cancer patients compared to non-cancer patients, particularly from parainfluenza virus and coronavirus 3 . The number of lung cancer patients with SARS-CoV-2 infection could be underestimated since the test is not routinely done in all symptomatic patients and the number of tests performed is not homogeneous even within a single nation like Italy, as reported by Carbone and Coll 4 ; therefore a large group of lung cancer patient may be positive but not recognized as such. An interesting report on 1,590 Chinese patients, showed that among them 18 had a history of cancer (1%) with lung cancer as the most frequent type (28%) and the 25% received surgery or chemotherapy in the last month 5 . Here we report the case of a 69 years old male patient affected by non squamous stage IV ALKpositive non small cell lung cancer (NSCLC) treated with first line Alectinib, admitted on March 15 2020 to the Emergency Room of local General Hospital due to worsening dyspnea, hacking cough and low-grade fever (37,5°C), unresponsive to acetaminophen and severe respiratory failure. Therapy with Alectinib started as first line at diagnosis in November 2018 and achieved PR as best response after 3 months. Response was still documented at last CT scan performed in February 2020 (Fig. 1A, 1B) . At hospital admittance, chest ultrasound showed bilateral subpleural interstitial thickening at lower lobes. Non-invasive ventilation (NIV) started soon due to severe hypoxia and a throat swab was found positive for SARS-CoV-2 by real time polymerase chain reaction (RT-PCR). Laboratory tests showed mild leukocytosis and a slight increase in C reactive protein. Alectinib was stopped and treatment with Lopinavir/Ritonavir coupled with hydroxychloroquine and twice daily subcutaneous enoxaparin started. Lopinavir/Ritonavir was discontinued after three days given the increase of total serum bilirubin levels (5.5 mg/dl). NIV continued for other 4 days, followed by Venturi mask at 60% with progressive respiratory improvement. Hydroxychloroquine and J o u r n a l P r e -p r o o f enoxaparin continued during hospitalization. A CT scan on April 2 2020 showed peripheral ubiquitous ground glass opacities, interlobular interstitial space thickening and irregular lower lobes consolidations, more evident at right lower lobe (Fig. 1C) . Respiratory function gradually improved and no other signs or symptoms of infection emerged, including fever. The patient was finally discharged on April 09 2020, without symptoms and with oxygen saturation of 99%. No therapy was further suggested at home and hydroxychloroquine was stopped. The first throat swab before patient discharge was still positive at RT-PCR; conversely a second one performed few days after was found negative. Alectinib was restarted the day after discharge at half dose for three days and then at full dose, without reporting any significant adverse event. A new CT scan performed on June 18 2020 during lung cancer follow-up, showed an almost complete resolution of the lung infiltrates (Fig. 1D ). At last follow-up visit the patient was still receiving Alectinib at full dose without any symptom related to COVID-19 or NSCLC. This is, to the best of our knowledge, the first reported case of ALK-positive advanced NSCLC successfully treated with Alectinib developing SARS-CoV-2 infection and COVID-19 with severe respiratory failure during targeted therapy and reporting a favourable outcome. Cancer is frequently associated with COVID-19 and lung cancer has been referred as the most frequent type among a large Chinese population; the 25% of cancer patients received surgery or chemotherapy in the month before infection 5 . However, few cases of COVID-19 in lung cancer patients have been reported to date. Zhang and Coll. recently described the case of a patient with EGFR-mutant NSCLC treated with Osimertinib during COVID-19, demonstrating the potential of continuing targeted therapy without any safety concern and maintaining response to Osimertinib 6 . Conversely, a fatal and rapid evolution of COVID-19 has been reported in a patient with adenocarcinoma treated for a long time with Nivolumab as second line 7 , suggesting a deleterious effect of PD1/PDL1 blockade during infection. This could be due to overlapping immunotherapyrelated lung toxicity and interstitial pneumonitis determined by SARS-CoV-2 or to enhanced immune function with immune-mediated lung injury facilitated by a "cytokine storm" described during infection 8 . More recently two cases of suspected SARS-CoV-2 infection have been described in an ALKpositive and a ROS1-positive NSCLC receiving targeted therapy 9 . In both cases RT-PCR on nasopharyngeal swab was negative, even if radiological signs and symptoms were highly J o u r n a l P r e -p r o o f suspicious for infection. Targeted agents, respectively Alectinib and Lorlatinib, were not discontinued 9 . In our case, first line Alectinib achieved a prompt radiological partial remission and a meaningful clinical improvement, persisting for 15 months until the occurrence of COVID-19. The patient experienced a favourable clinical evolution of COVID-19 without any significant worsening of NSCLC after 20-day break of the targeted agent. It has been also remarkable that no safety issues have emerged at the resumption of Alectinib, despite the increase of bilirubin serum level observed during antiviral treatment. However, we suggest caution during the coadministration of Alectinib and Lopinavir/Ritonavir, given their inhibitory effect on CYP3A cytochrome with potential increased exposure to Alectinib during the coadministration with hydroxychloroquine due to potential QTc prolongation. Treatment guidance during the COVID-19 pandemic have been published 10 but no guideline has been published to date for the treatment of NSCLC during SARS-CoV-2 infection and COVID-19 in selected population as patients with oncogene-addicted cancers receiving targeted agents. No definitive conclusion about Alectinib treatment during SARS-CoV-2 infection and COVID-19 can be drawn by this case. Caution has to be suggested in symptomatic patients and those with life threatening complications. Decision on continuing targeted agent must be carefully taken case by case, discussing also the potential interaction with other drugs administered to treat COVID-19 to avoid dangerous exposure. The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy. The Lancet WHO announces COVID-19 outbreak a pandemic High mortality from viral pneumonia in patients with cancer Editorial: Coronaviruses: Facts, Myths and Hypotheses Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2 A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab Pathological findings of COVID-19 associated with acute respiratory distress syndrome COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors Treatment guidance for lung cancer patients during the COVID-19 pandemic